Annals of Laboratory Medicine

Korean Society for Laboratory Medicine (대한진단검사의학회)
권호 표지
DOI QR코드

DOI QR Code

Measurable Residual Disease Testing Using Next-Generation Sequencing in Acute Myeloid Leukemia

  • Seon Young Kim (Department of Laboratory Medicine, Chungnam National University College of Medicine) ;
  • Hee Jin Huh (Department of Laboratory Medicine, Dongguk University Ilsan Hospital)
  • Published : 2023.07.01
Download PDF
⟨ Previous Next ⟩

Abstract

Keywords

References

  1. Schuurhuis GJ, Heuser M, Freeman S, Béné MC, Buccisano F, Cloos J, et al. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood 2018; 131:1275-91. https://doi.org/10.1182/blood-2017-09-801498
  2. Panuzzo C, Jovanovski A, Ali MS, Cilloni D, Pergolizzi B. Revealing the mysteries of acute myeloid leukemia: from quantitative PCR through next-generation sequencing and systemic metabolomic profiling. J Clin Med 2022;11:483. https://doi.org/10.3390/jcm11030483
  3. Wheeler FC, Kim AS, Mosse CA, Shaver AC, Yenamandra A, Seegmiller AC. Limited utility of fluorescence in situ hybridization for recurrent abnormalities in acute myeloid leukemia at diagnosis and follow-up. Am J Clin Pathol 2018;149:418-24. https://doi.org/10.1093/ajcp/aqy002
  4. Selim AG and Moore AS. Molecular minimal residual disease monitoring in acute myeloid leukemia: challenges and future directions. J Mol Diagn 2018;20:389-97.
  5. Chung HJ, Hur M, Yoon S, Hwang K, Lim HS, Kim H, et al. Performance evaluation of the QXDx BCR-ABL %IS droplet digital PCR assay. Ann Lab Med 2020;40:72-5. https://doi.org/10.3343/alm.2020.40.1.72
  6. Kim HY, Yoo IY, Lim DJ, Kim HJ, Kim SH, Yoon SE, et al. Clinical utility of next-generation flow-based minimal residual disease assessment in patients with multiple myeloma. Ann Lab Med 2022;42:558-65. https://doi.org/10.3343/alm.2022.42.5.558
  7. Kim H, Yun JW, Lee ST, Kim HJ, Kim SH, Kim JW, et al. Korean Society for Genetic Diagnostics guidelines for validation of next-generation sequencing-based somatic variant detection in hematologic malignancies. Ann Lab Med 2019;39:515-23. https://doi.org/10.3343/alm.2019.39.6.515
  8. Zhong Y, Xu F, Wu J, Schubert J, Li MM. Application of next generation sequencing in laboratory medicine. Ann Lab Med 2021;41:25-43. https://doi.org/10.3343/alm.2021.41.1.25
  9. Salipante SJ, Fromm JR, Shendure J, Wood BL, Wu D. Detection of minimal residual disease in NPM1-mutated acute myeloid leukemia by nextgeneration sequencing. Mod Pathol 2014;27:1438-46. https://doi.org/10.1038/modpathol.2014.57
  10. Levis MJ, Perl AE, Altman JK, Gocke CD, Bahceci E, Hill J, et al. A nextgeneration sequencing-based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations. Blood Adv 2018;2:825-31. https://doi.org/10.1182/bloodadvances.2018015925
  11. Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med 2016;374:2209-21. https://doi.org/10.1056/NEJMoa1516192
  12. Kim JJ, Jang JE, Lee HA, Park MR, Kook HW, Lee ST, et al. Development of a next-generation sequencing-based gene panel test to detect measurable residual disease in acute myeloid leukemia. Ann Lab Med 2023;43:328-40. https://doi.org/10.3343/alm.2023.43.4.328